Xopenex

See also: Generic Xopenex HFA

Xopenex is a brand name of levalbuterol, approved by the FDA in the following formulation(s):

XOPENEX (levalbuterol hydrochloride - solution; inhalation)

• 
  Manufacturer: SUNOVION
  
  Approval date: March 25, 1999
  
  Strength(s): EQ 0.021% BASE ^[RLD][AN], EQ 0.042% BASE ^[RLD][AN]


• 
  Manufacturer: SUNOVION
  
  Approval date: January 30, 2002
  
  Strength(s): EQ 0.0103% BASE ^[RLD][AN]


• 
  Manufacturer: SUNOVION
  
  Approval date: July 18, 2003
  
  Strength(s): EQ 0.25% BASE ^[RLD][AN]

Has a generic version of Xopenex been approved?

A generic version of Xopenex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Xopenex and have been approved by the FDA:

levalbuterol hydrochloride solution; inhalation

• 
  Manufacturer: DEY
  
  Approval date: March 20, 2009
  
  Strength(s): EQ 0.25% BASE ^[AN]


• 
  Manufacturer: WATSON LABS INC
  
  Approval date: April 9, 2008
  
  Strength(s): EQ 0.0103% BASE ^[AN], EQ 0.021% BASE ^[AN], EQ 0.042% BASE ^[AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xopenex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating asthma using optically pure (R)-albuterol
  Patent 5,362,755
  Issued: November 8, 1994
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with chronic administration of racemic albuterol.
  
  Patent expiration dates:
  
  
  • March 25, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM
  
  



• 
  Method for treating asthma using optically pure R(-) albuterol
  Patent 5,547,994
  Issued: August 20, 1996
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
  
  Patent expiration dates:
  
  
  • August 20, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM
  
  



• 
  Albuterol formulations
  Patent 6,451,289
  Issued: September 17, 2002
  Inventor(s): Robert J.; Wherry, III & Stewart H.; Mueller
  Assignee(s): Sepracor Inc.
  Albuterol formulations packaged in an oxygen-permeable plastic container have a long shelf life at room temperature. The formulations consist essentially of albuterol or a pharmaceutically acceptable salt thereof, sodium chloride, and water, have a pH of about 4, and contain less than 0.08% by weight of albuterol aldehyde and less than 1 ppm dissolved oxygen.
  
  Patent expiration dates:
  
  
  • March 21, 2021
    
  
  
  
  • March 21, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Xopenex Consumer Information (Drugs.com)
• Xopenex Solution Consumer Information (Wolters Kluwer)
• Xopenex Consumer Information (Cerner Multum)
• Xopenex Advanced Consumer Information (Micromedex)
• Xopenex AHFS DI Monographs (ASHP)
• Levalbuterol Aerosol Consumer Information (Wolters Kluwer)
• Levalbuterol Solution Consumer Information (Wolters Kluwer)
• Levalbuterol Consumer Information (Cerner Multum)
• Xopenex Pediatric Advanced Consumer Information (Micromedex)
• Levalbuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Levalbuterol AHFS DI Monographs (ASHP)